Report Detail

Request for Sample of this report

Other Global Lung Cancer Genomic Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4685465
    • |
  • 12 March, 2026
    • |
  • Global
    • |
  • 107 Pages
    • |
  • GIR
    • |
  • Other

According to our (Global Info Research) latest study, the global Lung Cancer Genomic Testing market size was valued at US$ 3095 million in 2025 and is forecast to a readjusted size of US$ 5574 million by 2032 with a CAGR of 9.1% during review period.
Lung cancer genomic testing comprises clinical molecular diagnostic assays used to identify actionable genetic alterations in lung cancer patients to guide targeted therapy, immunotherapy selection, and disease monitoring. Commonly tested biomarkers include EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, and NTRK, using PCR-based methods and next-generation sequencing (NGS) panels on tissue or liquid biopsy samples. From a value chain perspective, upstream inputs include sequencing platforms, reagents, probes, and bioinformatics infrastructure, midstream activities involve assay development, laboratory testing, quality control, and clinical interpretation, while downstream demand is driven by hospitals, oncology centers, pathology laboratories, and reference diagnostic labs.The industry maintains a 55%–75% gross margin, supported by high clinical value, reimbursement-backed demand, and increasing adoption of multi-gene profiling.
The market is rapidly shifting from single-gene assays to comprehensive NGS panels and liquid biopsy solutions. Competitive differentiation increasingly centers on panel breadth, turnaround time, companion diagnostic partnerships, and data interpretation capabilities rather than test price alone.
This report is a detailed and comprehensive analysis for global Lung Cancer Genomic Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Lung Cancer Genomic Testing market size and forecasts, in consumption value ($ Million), 2021-2032
Global Lung Cancer Genomic Testing market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Lung Cancer Genomic Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Lung Cancer Genomic Testing market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Lung Cancer Genomic Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Lung Cancer Genomic Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Thermo Fisher Scientific, Illumina, Agilent Technologies, QIAGEN, Guardant Health, Foundation Medicine, BGI Genomics, AmoyDx Diagnostics, Burning Rock Dx, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Lung Cancer Genomic Testing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Liquid Biopsy
Tissue Biopsy
Market segment by Testing Technology
PCR-based Assays
Next-generation Sequencing (NGS)
Market segment by Gene Coverage
Single-gene Testing
Multi-gene Panel
Comprehensive Genomic Profiling
Market segment by Application
Hospitals/Clinics
Research Organization
Diagnostic Laboratories
Market segment by players, this report covers
Roche
Thermo Fisher Scientific
Illumina
Agilent Technologies
QIAGEN
Guardant Health
Foundation Medicine
BGI Genomics
AmoyDx Diagnostics
Burning Rock Dx
Nanjing Geneseeq
Berry Oncology
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Lung Cancer Genomic Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Lung Cancer Genomic Testing, with revenue, gross margin, and global market share of Lung Cancer Genomic Testing from 2021 to 2026.
Chapter 3, the Lung Cancer Genomic Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Lung Cancer Genomic Testing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Lung Cancer Genomic Testing.
Chapter 13, to describe Lung Cancer Genomic Testing research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Lung Cancer Genomic Testing by Type
    • 1.3.1 Overview: Global Lung Cancer Genomic Testing Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Lung Cancer Genomic Testing Consumption Value Market Share by Type in 2025
    • 1.3.3 Liquid Biopsy
    • 1.3.4 Tissue Biopsy
  • 1.4 Classification of Lung Cancer Genomic Testing by Testing Technology
    • 1.4.1 Overview: Global Lung Cancer Genomic Testing Market Size by Testing Technology: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Lung Cancer Genomic Testing Consumption Value Market Share by Testing Technology in 2025
    • 1.4.3 PCR-based Assays
    • 1.4.4 Next-generation Sequencing (NGS)
  • 1.5 Classification of Lung Cancer Genomic Testing by Gene Coverage
    • 1.5.1 Overview: Global Lung Cancer Genomic Testing Market Size by Gene Coverage: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Lung Cancer Genomic Testing Consumption Value Market Share by Gene Coverage in 2025
    • 1.5.3 Single-gene Testing
    • 1.5.4 Multi-gene Panel
    • 1.5.5 Comprehensive Genomic Profiling
  • 1.6 Global Lung Cancer Genomic Testing Market by Application
    • 1.6.1 Overview: Global Lung Cancer Genomic Testing Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospitals/Clinics
    • 1.6.3 Research Organization
    • 1.6.4 Diagnostic Laboratories
  • 1.7 Global Lung Cancer Genomic Testing Market Size & Forecast
  • 1.8 Global Lung Cancer Genomic Testing Market Size and Forecast by Region
    • 1.8.1 Global Lung Cancer Genomic Testing Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Lung Cancer Genomic Testing Market Size by Region, (2021-2032)
    • 1.8.3 North America Lung Cancer Genomic Testing Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Lung Cancer Genomic Testing Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Lung Cancer Genomic Testing Market Size and Prospect (2021-2032)
    • 1.8.6 South America Lung Cancer Genomic Testing Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Lung Cancer Genomic Testing Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Lung Cancer Genomic Testing Product and Solutions
    • 2.1.4 Roche Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments and Future Plans
  • 2.2 Thermo Fisher Scientific
    • 2.2.1 Thermo Fisher Scientific Details
    • 2.2.2 Thermo Fisher Scientific Major Business
    • 2.2.3 Thermo Fisher Scientific Lung Cancer Genomic Testing Product and Solutions
    • 2.2.4 Thermo Fisher Scientific Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.3 Illumina
    • 2.3.1 Illumina Details
    • 2.3.2 Illumina Major Business
    • 2.3.3 Illumina Lung Cancer Genomic Testing Product and Solutions
    • 2.3.4 Illumina Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Illumina Recent Developments and Future Plans
  • 2.4 Agilent Technologies
    • 2.4.1 Agilent Technologies Details
    • 2.4.2 Agilent Technologies Major Business
    • 2.4.3 Agilent Technologies Lung Cancer Genomic Testing Product and Solutions
    • 2.4.4 Agilent Technologies Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Agilent Technologies Recent Developments and Future Plans
  • 2.5 QIAGEN
    • 2.5.1 QIAGEN Details
    • 2.5.2 QIAGEN Major Business
    • 2.5.3 QIAGEN Lung Cancer Genomic Testing Product and Solutions
    • 2.5.4 QIAGEN Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 QIAGEN Recent Developments and Future Plans
  • 2.6 Guardant Health
    • 2.6.1 Guardant Health Details
    • 2.6.2 Guardant Health Major Business
    • 2.6.3 Guardant Health Lung Cancer Genomic Testing Product and Solutions
    • 2.6.4 Guardant Health Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Guardant Health Recent Developments and Future Plans
  • 2.7 Foundation Medicine
    • 2.7.1 Foundation Medicine Details
    • 2.7.2 Foundation Medicine Major Business
    • 2.7.3 Foundation Medicine Lung Cancer Genomic Testing Product and Solutions
    • 2.7.4 Foundation Medicine Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Foundation Medicine Recent Developments and Future Plans
  • 2.8 BGI Genomics
    • 2.8.1 BGI Genomics Details
    • 2.8.2 BGI Genomics Major Business
    • 2.8.3 BGI Genomics Lung Cancer Genomic Testing Product and Solutions
    • 2.8.4 BGI Genomics Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 BGI Genomics Recent Developments and Future Plans
  • 2.9 AmoyDx Diagnostics
    • 2.9.1 AmoyDx Diagnostics Details
    • 2.9.2 AmoyDx Diagnostics Major Business
    • 2.9.3 AmoyDx Diagnostics Lung Cancer Genomic Testing Product and Solutions
    • 2.9.4 AmoyDx Diagnostics Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 AmoyDx Diagnostics Recent Developments and Future Plans
  • 2.10 Burning Rock Dx
    • 2.10.1 Burning Rock Dx Details
    • 2.10.2 Burning Rock Dx Major Business
    • 2.10.3 Burning Rock Dx Lung Cancer Genomic Testing Product and Solutions
    • 2.10.4 Burning Rock Dx Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Burning Rock Dx Recent Developments and Future Plans
  • 2.11 Nanjing Geneseeq
    • 2.11.1 Nanjing Geneseeq Details
    • 2.11.2 Nanjing Geneseeq Major Business
    • 2.11.3 Nanjing Geneseeq Lung Cancer Genomic Testing Product and Solutions
    • 2.11.4 Nanjing Geneseeq Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Nanjing Geneseeq Recent Developments and Future Plans
  • 2.12 Berry Oncology
    • 2.12.1 Berry Oncology Details
    • 2.12.2 Berry Oncology Major Business
    • 2.12.3 Berry Oncology Lung Cancer Genomic Testing Product and Solutions
    • 2.12.4 Berry Oncology Lung Cancer Genomic Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Berry Oncology Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Lung Cancer Genomic Testing Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Lung Cancer Genomic Testing by Company Revenue
    • 3.2.2 Top 3 Lung Cancer Genomic Testing Players Market Share in 2025
    • 3.2.3 Top 6 Lung Cancer Genomic Testing Players Market Share in 2025
  • 3.3 Lung Cancer Genomic Testing Market: Overall Company Footprint Analysis
    • 3.3.1 Lung Cancer Genomic Testing Market: Region Footprint
    • 3.3.2 Lung Cancer Genomic Testing Market: Company Product Type Footprint
    • 3.3.3 Lung Cancer Genomic Testing Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Lung Cancer Genomic Testing Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Lung Cancer Genomic Testing Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Lung Cancer Genomic Testing Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Lung Cancer Genomic Testing Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Lung Cancer Genomic Testing Consumption Value by Type (2021-2032)
  • 6.2 North America Lung Cancer Genomic Testing Market Size by Application (2021-2032)
  • 6.3 North America Lung Cancer Genomic Testing Market Size by Country
    • 6.3.1 North America Lung Cancer Genomic Testing Consumption Value by Country (2021-2032)
    • 6.3.2 United States Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Lung Cancer Genomic Testing Consumption Value by Type (2021-2032)
  • 7.2 Europe Lung Cancer Genomic Testing Consumption Value by Application (2021-2032)
  • 7.3 Europe Lung Cancer Genomic Testing Market Size by Country
    • 7.3.1 Europe Lung Cancer Genomic Testing Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 7.3.3 France Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Lung Cancer Genomic Testing Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Lung Cancer Genomic Testing Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Lung Cancer Genomic Testing Market Size by Region
    • 8.3.1 Asia-Pacific Lung Cancer Genomic Testing Consumption Value by Region (2021-2032)
    • 8.3.2 China Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 8.3.5 India Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Lung Cancer Genomic Testing Consumption Value by Type (2021-2032)
  • 9.2 South America Lung Cancer Genomic Testing Consumption Value by Application (2021-2032)
  • 9.3 South America Lung Cancer Genomic Testing Market Size by Country
    • 9.3.1 South America Lung Cancer Genomic Testing Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Lung Cancer Genomic Testing Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Lung Cancer Genomic Testing Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Lung Cancer Genomic Testing Market Size by Country
    • 10.3.1 Middle East & Africa Lung Cancer Genomic Testing Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Lung Cancer Genomic Testing Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Lung Cancer Genomic Testing Market Drivers
  • 11.2 Lung Cancer Genomic Testing Market Restraints
  • 11.3 Lung Cancer Genomic Testing Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Lung Cancer Genomic Testing Industry Chain
  • 12.2 Lung Cancer Genomic Testing Upstream Analysis
  • 12.3 Lung Cancer Genomic Testing Midstream Analysis
  • 12.4 Lung Cancer Genomic Testing Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Lung Cancer Genomic Testing. Industry analysis & Market Report on Lung Cancer Genomic Testing is a syndicated market report, published as Global Lung Cancer Genomic Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Lung Cancer Genomic Testing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo